Tags

Type your tag names separated by a space and hit enter

Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997).
J Clin Microbiol. 2003 Jan; 41(1):483-5.JC

Abstract

Listeriosis is a serious complication in patients undergoing treatment for cancer. We present antimicrobial susceptibility profiles of 84 clinical Listeria monocytogenes isolates. During 1955 to 1997, in vitro susceptibility for penicillin (97.6%), ampicillin (90.7%), erythromycin (98.8%), tetracycline (96.9%), and gentamicin (98.0%) remained unchanged. All isolates were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin. High prevalence of clindamycin resistance (96.2%) was unexpected. Ampicillin plus gentamicin is standard therapy for systemic listerosis, and TMP-SMX may be used for patients with beta-lactam intolerance. In vitro susceptibility profiles for carbapenem and fluoronated quinolone are promising, although clinical validation is critically needed before routine use is advocated, especially for listeric patients with severe cellular immune defects.

Authors+Show Affiliations

Memorial Sloan-Kettering Cancer Center, New York, New York 10021,USA. asafdar@mdanderson.orgNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12517901

Citation

Safdar, Amar, and Donald Armstrong. "Antimicrobial Activities Against 84 Listeria Monocytogenes Isolates From Patients With Systemic Listeriosis at a Comprehensive Cancer Center (1955-1997)." Journal of Clinical Microbiology, vol. 41, no. 1, 2003, pp. 483-5.
Safdar A, Armstrong D. Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). J Clin Microbiol. 2003;41(1):483-5.
Safdar, A., & Armstrong, D. (2003). Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). Journal of Clinical Microbiology, 41(1), 483-5.
Safdar A, Armstrong D. Antimicrobial Activities Against 84 Listeria Monocytogenes Isolates From Patients With Systemic Listeriosis at a Comprehensive Cancer Center (1955-1997). J Clin Microbiol. 2003;41(1):483-5. PubMed PMID: 12517901.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimicrobial activities against 84 Listeria monocytogenes isolates from patients with systemic listeriosis at a comprehensive cancer center (1955-1997). AU - Safdar,Amar, AU - Armstrong,Donald, PY - 2003/1/9/pubmed PY - 2003/5/8/medline PY - 2003/1/9/entrez SP - 483 EP - 5 JF - Journal of clinical microbiology JO - J. Clin. Microbiol. VL - 41 IS - 1 N2 - Listeriosis is a serious complication in patients undergoing treatment for cancer. We present antimicrobial susceptibility profiles of 84 clinical Listeria monocytogenes isolates. During 1955 to 1997, in vitro susceptibility for penicillin (97.6%), ampicillin (90.7%), erythromycin (98.8%), tetracycline (96.9%), and gentamicin (98.0%) remained unchanged. All isolates were susceptible to amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin. High prevalence of clindamycin resistance (96.2%) was unexpected. Ampicillin plus gentamicin is standard therapy for systemic listerosis, and TMP-SMX may be used for patients with beta-lactam intolerance. In vitro susceptibility profiles for carbapenem and fluoronated quinolone are promising, although clinical validation is critically needed before routine use is advocated, especially for listeric patients with severe cellular immune defects. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/12517901/Antimicrobial_activities_against_84_Listeria_monocytogenes_isolates_from_patients_with_systemic_listeriosis_at_a_comprehensive_cancer_center_(1955-1997) L2 - http://jcm.asm.org/cgi/pmidlookup?view=long&pmid=12517901 DB - PRIME DP - Unbound Medicine ER -